Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)

Hans‐Peter Hartung; Lawrence Steinman; Amit Bar‐Or; James K. Sheffield; Sarah Harris; Jon Riolo; Chun-Yen Cheng; Jennifer Reardon; Andrew Thorpe; Bruce Cree

doi:10.1212/wnl.0000000000204936

April 9, 2024Neurology

Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Describe absolute lymphocyte count (ALC) at the time of a first infection in participants with relapsing multiple sclerosis treated with ozanimod 0.92 mg/d in phase 3 "parent" trials (SUNBEAM–NCT02294058; RADIANCE–NCT02047734) and an open-label extension (OLE) trial (DAYBREAK–NCT02576717).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hartung et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdb8b6db6435876783c3 https://doi.org/10.1212/wnl.0000000000204936

View at Publisher

Ask AI

Bookmark

Share

Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)

Ask about this paper

Abstract

Discussion

Cite This Study

Absolute Lymphocyte Count Around Infections During Phase 3 and Open-label Extension Trials of Ozanimod in Participants with Relapsing Multiple Sclerosis (P10-6.013)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading